Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Christi L. Shaw will join the company as Chief Executive Officer of Kite, a Gilead Company, and will become a member of Gilead’s senior leadership team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190711005777/en/
Ms. Shaw is a renowned leader with deep experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry. Ms. Shaw currently serves as Senior Vice President of Eli Lilly &. Co., and President of Lilly Bio-Medicines. She also serves as a board member of both Avantor, Inc. and the Biotechnology Industry Organization (BIO), and as an advisor to the Healthcare Businesswomen’s Association.
Prior to joining Lilly, Ms. Shaw most recently served as U.S. Country Head and President of Novartis Corp. and North American Head of Novartis Oncology. She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin.
“We conducted an extensive search for a new leader at Kite and we believe that Christi’s unique set of skills will allow us to continue to build on our leadership position in cell therapy,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Christi’s vast experience across complex therapeutic areas, and particularly in oncology, will serve Kite very well. She is clearly a leader who will bring teams and individuals together and I am confident she will build upon the entrepreneurial spirit at Kite as we seek to help more people with cancer around the world.”
“Kite’s vision of transformational drug development – and of curing cancer – is one that I am extremely passionate about,” said Ms. Shaw. “I look forward to working with the many talented individuals in this organization, as we change the way cancer is treated and bring forward important, life-saving therapies.”
Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
For more information on Kite, please visit the company’s website at www.kitepharma.com. Learn more about Gilead at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
Shant Salakian, Media
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ResMed Inc. Completes $500M Private Placement Debt Offering15.7.2019 20:05:00 CEST | Press release
ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility. The notes are senior unsecured obligations of ResMed, and jointly and severally guaranteed by each Subsidiary Guarantor. “We are pleased to complete this U.S. private placement offering on attractive terms,” said Brett Sandercock, ResMed’s chief financial officer. “The transaction significantly lengthens our average debt maturity profile and provides improved visibility on our long-term funding costs.” This private placement offering is exempt from the registration requirements of t
SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test15.7.2019 15:00:00 CEST | Press release
SpeeDx Pty. Ltd. today announced Resistance Plus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mgen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005544/en/ (Photo: Business Wire) Current Canadian management guidelines for Mgen direct laboratories to forward positive samples to the National Microbiology Laboratory for resistance testing.1 Now Canadian laboratories can utilize Resistance Plus MG and bring this service inhouse to generate more timely results for doctors and their p
Mouser Electronics Now Stocking Broad Portfolio of Xilinx Products15.7.2019 14:55:00 CEST | Press release
Mouser Electronics, Inc. today announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing, to stock one of the industry’s broadest portfolios of Xilinx products, including digital downloads of development software and IP. Xilinx is the inventor of the FPGA, hardware programmable system-on-chips (SoCs) and the adaptive compute acceleration platform (ACAP), designed to deliver the most dynamic processor technology in the industry and enable the adaptable, intelligent and connected world of the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005546/en/ Mouser Electronics proudly announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing. Mouser will stock one of the industry’s broadest portfolios of Xilinx products. (Graphic: Business Wire) To learn more, visit www.mouser.com/xilinx. “Xilinx is an industry
Rimini Street Becomes Support Service Provider for Hyundai-Kia Motors’ Global Database Portfolio15.7.2019 13:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005161/en/ Rimini Street announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. (Photo: Business Wire) By providing efficient, timely, and cost-effective database maintenance and support, Rimini Street plans to actively support Hyundai-Kia Motors in their endeavor to implement a business-driven IT roadmap. Cost Optimization and Desire for Quality Support To support response to paradigm shifts in the automobile industry and active technology innovation, Hyundai-Kia Motors se
Värde Partners Appoints Co-CEO15.7.2019 12:12:00 CEST | Press release
Värde Partners, a leading global alternative investment firm, today announced that Ilfryn Carstairs will join George Hicks, Co-Founder and Chief Executive Officer, as Co-CEO, effective January 1, 2020. George co-founded Värde Partners 25 years ago and intends to transition to an Executive Chair role in 2022. Ilfryn will retain his role as Global CIO. “Transition is a process and involves the entirety of the firm. The roles Ilfryn and I play are just part of that process whereby a new generation of leaders succeed the founders,” said George. “Ilfryn joined us 12 years into this journey and has grown as both an investor and a leader. His skills in both pursuits will enable Värde to continue delivering for our investors and will help to ensure that we maintain our strong culture long into the future.” Ilfryn is a Partner and Co-Chief Investment Officer overseeing the global investment strategy for Värde. He co-chairs the firm’s Investment Committee. Based in Singapore since 2017, he joine
Sintavia Acquires QC Laboratories15.7.2019 12:00:00 CEST | Press release
Sintavia, LLC, the leading independent additive manufacturer supporting the Aerospace & Defense industry, announced today that it had acquired QC Laboratories, Inc. (“QC Labs”), a non-destructive testing (“NDT”) services company based in Hollywood, Florida. The acquisition greatly enhances Sintavia’s NDT capabilities for commercial aerospace applications, particularly with respect to surface finish conformance testing. Post-closing, it is expected that QC Labs will operate as a stand-alone subsidiary of Sintavia. Additional terms of the transaction were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005099/en/ Sintavia's 55,000 square foot advanced manufacturing facility, located in Hollywood, Florida, specializing in metal additive manufacturing. (Photo: Business Wire) “We have worked with QC Labs for a number of years to develop surface finish inspection metrics that are relevant for the additive manuf